5 Stocks Pulling The Drugs Industry Downward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 91 points (-0.6%) at 15,838 as of Wednesday, Jan. 29, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 929 issues advancing vs. 2,026 declining with 145 unchanged.

The Drugs industry currently sits down 0.5% versus the S&P 500, which is down 0.4%. On the negative front, top decliners within the industry include GlaxoSmithKline ( GSK), down 1.9%, Sanofi ( SNY), down 1.3% and Novo Nordisk A/S ( NVO), down 1.1%. A company within the industry that increased today was Medivation ( MDVN), up 12.2%.

TheStreet would like to highlight 5 stocks pushing the industry lower today:

5. AstraZeneca ( AZN) is one of the companies pushing the Drugs industry lower today. As of noon trading, AstraZeneca is down $0.46 (-0.7%) to $63.63 on light volume. Thus far, 490,951 shares of AstraZeneca exchanged hands as compared to its average daily volume of 2.2 million shares. The stock has ranged in price between $63.28-$63.79 after having opened the day at $63.39 as compared to the previous trading day's close of $64.09.

AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for cardiovascular, gastrointestinal, neuroscience, infection, oncology, and respiratory and inflammation diseases worldwide. AstraZeneca has a market cap of $80.1 billion and is part of the health care sector. The company has a P/E ratio of 12.8, below the S&P 500 P/E ratio of 17.7. Shares are up 8.0% year-to-date as of the close of trading on Tuesday. Currently there are 2 analysts that rate AstraZeneca a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates AstraZeneca as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, largely solid financial position with reasonable debt levels by most measures, attractive valuation levels, expanding profit margins and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full AstraZeneca Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

4. As of noon trading, Actavis ( ACT) is down $1.71 (-0.9%) to $182.45 on average volume. Thus far, 522,702 shares of Actavis exchanged hands as compared to its average daily volume of 1.3 million shares. The stock has ranged in price between $181.46-$183.83 after having opened the day at $183.08 as compared to the previous trading day's close of $184.16.

Actavis plc, an integrated specialty pharmaceutical company, develops, manufactures, markets, and distributes pharmaceutical products in the United States, Canada, and internationally. Actavis has a market cap of $31.1 billion and is part of the health care sector. Shares are up 9.6% year-to-date as of the close of trading on Tuesday. Currently there are 12 analysts that rate Actavis a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Actavis as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, generally higher debt management risk and disappointing return on equity. Get the full Actavis Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

3. As of noon trading, Bristol-Myers Squibb Company ( BMY) is down $0.65 (-1.3%) to $50.42 on average volume. Thus far, 3.6 million shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 8.0 million shares. The stock has ranged in price between $50.33-$51.23 after having opened the day at $50.72 as compared to the previous trading day's close of $51.07.

Bristol-Myers Squibb Company, a biopharmaceutical company, discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products that help patients prevail over serious diseases worldwide. Bristol-Myers Squibb Company has a market cap of $81.9 billion and is part of the health care sector. The company has a P/E ratio of 27.3, above the S&P 500 P/E ratio of 17.7. Shares are down 3.9% year-to-date as of the close of trading on Tuesday. Currently there are 10 analysts that rate Bristol-Myers Squibb Company a buy, 1 analyst rates it a sell, and 6 rate it a hold.

TheStreet Ratings rates Bristol-Myers Squibb Company as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, compelling growth in net income, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Bristol-Myers Squibb Company Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Merck ( MRK) is down $0.62 (-1.2%) to $52.25 on average volume. Thus far, 6.2 million shares of Merck exchanged hands as compared to its average daily volume of 12.2 million shares. The stock has ranged in price between $52.16-$52.84 after having opened the day at $52.70 as compared to the previous trading day's close of $52.87.

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products worldwide. Merck has a market cap of $153.5 billion and is part of the health care sector. The company has a P/E ratio of 35.3, above the S&P 500 P/E ratio of 17.7. Shares are up 5.6% year-to-date as of the close of trading on Tuesday. Currently there are 5 analysts that rate Merck a buy, 1 analyst rates it a sell, and 8 rate it a hold.

TheStreet Ratings rates Merck as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Merck Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Pfizer ( PFE) is down $0.20 (-0.7%) to $30.22 on average volume. Thus far, 10.4 million shares of Pfizer exchanged hands as compared to its average daily volume of 24.1 million shares. The stock has ranged in price between $30.00-$30.46 after having opened the day at $30.24 as compared to the previous trading day's close of $30.42.

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells medicines for people and animals worldwide. Pfizer has a market cap of $192.2 billion and is part of the health care sector. The company has a P/E ratio of 19.6, above the S&P 500 P/E ratio of 17.7. Shares are down 0.7% year-to-date as of the close of trading on Tuesday. Currently there are 7 analysts that rate Pfizer a buy, 1 analyst rates it a sell, and 4 rate it a hold.

TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, good cash flow from operations, increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Pfizer Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Asian Markets Decline in Morning Trading

Asian Markets Decline in Morning Trading

Verizon Proves Resilient in Sell-Off; Decoding the Facebook Short -- ICYMI

Verizon Proves Resilient in Sell-Off; Decoding the Facebook Short -- ICYMI

Three Big Factors That Rocked the Stock Market Tuesday

Three Big Factors That Rocked the Stock Market Tuesday

Dow Tumbles Over 400 Points; S&P 500 and Nasdaq Also Finish Lower

Dow Tumbles Over 400 Points; S&P 500 and Nasdaq Also Finish Lower

Caterpillar Bulldozes Industrial Sector With Bad News on Earnings Call

Caterpillar Bulldozes Industrial Sector With Bad News on Earnings Call